From Awareness to Action: The Next Era of Allergy Drug Development

The Growing Burden of Allergic Disease

Immune-mediated allergic diseases, including asthma, atopic dermatitis, food allergy, allergic rhinitis, and anaphylaxis, now affect hundreds of millions of people globally. 

Historically, allergic diseases were viewed primarily through the lens of IgE-mediated hypersensitivity. Today, advances in immunology have revealed a far more complex picture in which epithelial barrier dysfunction, innate immune activation, adaptive immune responses, and intricate cytokine networks orchestrate type 2 inflammation. This deeper mechanistic understanding is reshaping not only how we think about disease intervention, but how new therapies are developed. 

The Era of Precision Immunology Has Arrived

Over the past decade, allergy therapeutics have moved beyond symptom management toward targeted immune modulation. The success of anti-IgE therapy demonstrated that selective intervention could alter disease biology rather than simply suppress symptoms. More recently, therapies targeting IL-4 and IL-13 signalling have transformed the treatment landscape for atopic dermatitis and severe asthma. The approval of TSLP-targeting therapies has further validated the concept that intervening upstream in the inflammatory cascade can deliver broad clinical benefit across multiple patient populations.

Perhaps most exciting has been the rapid progress in food allergy. In 2024, the OUtMATCH study demonstrated that Xolair® (omalizumab) significantly reduced allergic reactions to multiple food allergens, representing a major advancement beyond traditional allergen avoidance strategies. The arrival in 2025 of the first interchangeable omalizumab biosimilar promises to widen access to a therapy whose value is now firmly established, whilst investigational multi-allergen oral immunotherapies and renewed interest in sublingual approaches point towards regimens capable of addressing several sensitivities at once. In late 2025, epicutaneous immunotherapy the peanut “patch” reported positive pivotal results in young children, with roughly three times as many treated children meeting the response threshold as those receiving placebo, supporting progression towards regulatory submission. 

Most novel of all, perhaps, are first-in-class antibodies engineered to neutralise specific aeroallergens directly among them the dominant cat and birch allergens which have reported encouraging Phase 3 results and are advancing further in 2026. Similarly, biologics targeting epithelial-derived cytokines such as IL-33 continue to show encouraging clinical results, highlighting the growing importance of barrier-driven biology in allergic disease.

Collectively, these advances point toward a future where allergy treatment becomes increasingly personalised, mechanism-driven, and preventative.

Anaphylaxis Reveals the Complexity of Allergic Biology

While therapeutic precision is increasing, so is biological complexity.

Anaphylaxis provides a particularly useful lens through which to view this challenge. Although commonly recognised as an acute clinical emergency, anaphylaxis is fundamentally a mechanistic immunology problem.

Classically, severe allergic reactions are driven by allergen-specific IgE bound to FcεRI receptors on mast cells and basophils. Allergen-mediated receptor crosslinking triggers rapid degranulation, releasing histamine and other inflammatory mediators that drive systemic symptoms such as vascular leakage, bronchoconstriction and multi-system involvement - but the pathways leading to it are broader than initially appreciated.

However, emerging evidence suggests that this classical model represents only part of the story. The identification of MRGPRX2 a mast-cell-expressed G-protein-coupled receptor activated by an array of cationic ligands, including certain neuropeptides, host-defence peptides and even approved drugs has illuminated an IgE-independent route to degranulation, long suspected but poorly defined. Strikingly, recent work in humanised knock-in models suggests that MRGPRX2 may also amplify classical IgE-mediated systemic anaphylaxis, blurring a once-thought clear distinction.

Alternative mast cell activation pathways, basophil contributions, epithelial-derived cytokines including TSLP and IL-33, and tissue-specific inflammatory responses all contribute to disease severity and patient heterogeneity. Small changes within these signalling networks can significantly alter the threshold for systemic immune activation.

For developers of next-generation therapeutics, understanding these interactions is no longer optional; it is essential to predicting both efficacy and safety. For example, RoukenBio’s IgE-mediated reporter and degranulation assays can evaluate target engagement, inhibitory activity, and anaphylactic risk, while primary immune cell platforms support mechanistic insights into inflammatory signalling and immune modulation.

The Translational Gap in Allergy Research

Our biological understanding has, however, outpaced the experimental systems used to interrogate it. Many established assay systems still rely on isolated cell types, limited endpoints, or simplified activation models that inadequately represent the complexity of human allergic disease.

As therapeutic strategies become more targeted, developers face increasingly sophisticated questions:

• Which pathway is being modulated?
• How does pathway modulation translate across multiple immune cell populations?
• Does intervention reduce disease-driving inflammation without creating unintended effects elsewhere in the immune network?
• Can we predict how a therapy might influence the threshold for severe allergic responses?

Answering these questions requires more than efficacy measurements. It requires mechanistically informed experimental systems capable of reproducing the biology that therapies are designed to modify.

Building Human-Relevant Models for the Next Generation of Allergy Therapeutics

At RoukenBio, we see this challenge reflected across an increasing number of discovery and translational programmes. The direction of travel is clear: therapies are becoming more targeted, with increasing focus on upstream biology, immune regulation, and prevention of severe outcomes such as anaphylaxis. What is still evolving is the ability to translate that biology into experimental systems that support confident decisions early.

This is where the role of CROs is changing. The expectation is no longer limited to execution, but to work alongside developers to translate complex biology into tractable, testable systems, connecting pathway biology with assay design in a way that is both mechanistically grounded and decision relevant.

Our approach focuses on building a continuous view of allergic biology, rather than interrogating individual components in isolation. Leveraging advanced allergy assays, immunology expertise, and translational disease models, we generate actionable data to support allergy drug discovery, therapeutic development, biomarker identification, and preclinical candidate evaluation.

Through the integration of reporter platforms for FcεRI signalling, IL-4/IL-13 pathway activity, and TSLP-driven responses with functional mast cell, basophil, and epithelial cell models, we capture key biological events across the allergic cascade. This approach enables the characterization of allergic responses from epithelial barrier activation and innate immune signalling through type 2 inflammatory amplification and downstream effector cell activation, providing a continuous and translational view of allergic biology for therapeutic development.

This includes:

• Quantitative reporter systems for key allergy-relevant signalling pathways
• Functional mast cell activation and degranulation assays spanning both IgE-dependent and independent (MRGPRX2- mediated) responses
• Basophil activation platforms providing orthogonal assessment of effector responses
• Advanced air-liquid interface epithelial models that capture barrier dysfunction and alarmin release
• Integrated workflows that connect upstream signalling with downstream functional outcomes

Together, these systems reduce uncertainty at key decisions during target validation, candidate selection, mechanism-of-action studies, and early safety assessments and help our partners advance the right molecules with greater confidence. 

Looking Ahead: From Reaction to Resolution

The broader immunology landscape is converging on a single principle: that successful therapies are increasingly built on a deep understanding of biological mechanism.

We have already witnessed this evolution in oncology and autoimmune disease. Allergy is now following a similar trajectory, characterised by targeted immune modulation, biomarker-guided development, and an increasing reliance on human-relevant translational systems.

The opportunity ahead is substantial. Advances in biologics, precision immunology, and systems-based approaches are creating new possibilities to prevent severe allergic outcomes and potentially modify disease trajectories altogether.

As we mark World Allergy Awareness Week, it is worth recognising that awareness is only the beginning. Real progress will depend on our ability to translate biological insight into experimental systems that support confident decision-making and accelerate the development of the next generation of allergy therapeutics.

The future of allergy research lies not simply in understanding immune responses, but in modelling them with sufficient precision to control them.